Detection of FLT3 Gene Mutations in Patients With Acute Myeloid Leukemia in Surabaya, Indonesia: A Single-Center Study

Background: flt3 gene mutation contributes worse prognosis in patients with acute myeloid leukemia (aml). almost 67% of patients with aml with flt3 gene mutation cannot reach complete remission after induction therapy, and they are also at high risk of relapse. we aimed to investigate the flt3-itd, -tkd (d835) gene mutation prevalence in patients with aml at surabaya and their association with leukocyte and bone marrow blast cell count. methods: 20 de novo patients with aml were recruited during february–july 2018. they were investigated through routine aml check-up and detection for flt3-itd, -tkd (d835) gene mutation. results: four patients with de novo aml (20%) had flt3-itd gene mutation, and one patient had flt3-tkd (d835) gene mutation. median leukocyte count in patients with aml with flt3-itd mutation was higher than wild type patients ( 146.3×10^3/ μl vs 16.4 x 10^3 / μl, p=0,002). the mean bone marrow blast cell count was higher in patients with aml with flt3-itd mutation than wild type patients ( 86.5% vs 57.9%, p=0,047). the difference in leukocyte and bone marrow blast cell count in patients with flt3-tkd (d835) mutation could not be analyzed since there was only one patient with this mutation. conclusion: the prevalence of flt3-itd gene mutation in patients in aml in surabaya was 20% and flt3-tkd (d835) was 5%. patients with flt3-itd gene mutation was associated with leukocyte and bone marrow blast cell count.